Daiichi Sankyo Company, Limited announced that it has initiated a Phase III pivotal study of CS-3150 (esaxerenone (r-INN)), its non-steroidal,...
IsoRay has announced a peer-reviewed publication of the results of a retrospective study on the cost effectiveness of Cesium-131 Brachytherapy...
In a Phase III clinical trial of Ilaris (canakinumab), from Novartis, patients (2-19 years of age) with active systemic Juvenile...
The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to...
Roche announced that the European Commission has approved MabThera (rituximab) for the treatment of adults with moderate to severe pemphigus...
The coronary sinus (CS) Reducer is a novel device designed to aid in the management and to improve quality of life of patients with severe angina symptoms refractory to optimal medical and interventional therapies.
Xeris Biopharma announced that the European Journal of Endocrinology (EJE) published the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating longer-term effects of Recorlev (levoketoconazole) on cortisol levels, biomarkers of Cushing’s syndrome (CS) comorbidities, clinical signs and symptoms of CS, and quality of life. The manuscript also reports findings from pituitary adenoma imaging in the SONICS study
LX 1032 (telotristat etiprate), from Lexicon Pharmaceuticals, for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in...
Genentech, a member of the Roche Group announced that the FDA has approved Rituxan (rituximab) for the treatment of adults...